|Awarded On||August 19, 2020|
|Title||Harnessing Aurora Kinase Inhibition-Induced Cell Death to Enhance Immunotherapy in HPV- Driven Cancers|
|Award Mechanism||Individual Investigator Research Awards for Clinical Translation|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Jagannadha Sastry|
|Cancer Sites||Cervix Uteri, Head and Neck, Penis|
*Pending contract negotiation
Human papillomavirus (HPV)-driven cancers are common and lethal. There are no effective targeted therapies for HPV+ cancers. Most of those who progress after initial therapy with radiation and chemotherapy die within 3 years, demonstrating unmet clinical need. Immunotherapy (ICT) is effective for recurrent HPV+ cancers, but with response rates of and a one-year survival rate of 40%. To address the unmet need for biomarker-driven therapy for HPV+ cancers, we tested the efficacy of 721 drugs in HPV+ and negative cell lines and identified Aurora kinase inhibitors as the only class of drugs that was more effective in HPV+ cell lines. We demonstrated that Aurora kinase inhibition leads to HPV+ ca...